Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis
Tue, 09/01/2026 – 07:17
Read more about Novartis remibrutinib, a high-efficacy…
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis
Wed, 08/19/2026 – 07:19
Read more about Novartis data at ESC Congress 2026 reinforce cardiovascular leadership…
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
arcticnovartis
Wed, 08/19/2026 – 07:19
Read more about Novartis data at ESC Congress 2026 reinforce cardiovascular leadership…
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
arcticnovartis
Fri, 07/31/2026 – 22:29
Read more about FDA approves Pluvicto for PSMA+ metasta…
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
arcticnovartis
Tue, 07/21/2026 – 07:03
Read more about Novartis verzeichnete im zweiten Quartal Umsatzsteigeru…
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
arcticnovartis
Tue, 07/21/2026 – 07:02
Read more about Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidan…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis
Fri, 07/17/2026 – 01:19
Read more about Novartis Fabhalta® (iptaco…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis
Fri, 07/17/2026 – 01:19
Read more about Novartis Fabhalta® (iptaco…
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
arcticnovartis
Mon, 07/06/2026 – 07:03
Read more about Novartis agrees to acquire …
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis
Thu, 07/02/2026 – 07:04
Read more about Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
…